Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT
NCT07527806Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of trastuzumab rezetecan, trastuzumab deruxtecan in breast cancer, sponsored by Peking University Cancer Hospital & Institute. Planned start May 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecantrastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07527806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07527806.